Your browser doesn't support javascript.
loading
A novel lncRNA MTAR1 promotes cancer development through IGF2BPs mediated post-transcriptional regulation of c-MYC.
Gao, Yunfeng; Jiang, Ming; Guo, Fangqin; Liu, Xuejiao; Zhang, Qi; Yang, Sen; Yeung, Yiu To; Yang, Ran; Wang, Keke; Wu, Qiong; Zhang, Dandan; Zhang, Chengjuan; Laster, Kyle Vaughn; Ge, Mengmeng; Nie, Wenna; Liu, Kangdong; Dong, Zigang.
Afiliação
  • Gao Y; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Jiang M; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Guo F; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Liu X; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Zhang Q; Pathophysiology Department, The School of Basic Medical Sciences, AMS, Zhengzhou University, Zhengzhou, 450000, China.
  • Yang S; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Yeung YT; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Yang R; Medical Research Council (MRC) Centre of Reproductive Health, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, EH16 4TJ, Scotland, UK.
  • Wang K; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Wu Q; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Zhang D; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Zhang C; Pathophysiology Department, The School of Basic Medical Sciences, AMS, Zhengzhou University, Zhengzhou, 450000, China.
  • Laster KV; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Ge M; Department of Molecular Pathology Central Biorepository, Henan Cancer Hospital, Zhengzhou, 450000, China.
  • Nie W; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Liu K; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
  • Dong Z; China-US (Henan) Hormel Cancer Institute, Zhengzhou, 450000, China.
Oncogene ; 41(42): 4736-4753, 2022 10.
Article em En | MEDLINE | ID: mdl-36109629
Abnormal translation of the MYC proto-oncogene is a hallmark of the initiation and maintenance of tumorigenesis. However, the molecular mechanism underlying increased MYC protein levels in certain cancer types without a corresponding increase in MYC mRNA levels is unclear. Here, we identified a novel lncRNA, MTAR1, which is critical for post-transcriptional regulation of MYC-induced tumorigenesis. MTAR1 is essential for recruiting IGF2BPs into PABP1-mediated liquid-liquid phase separation (LLPS) complexes and facilitates IGF2BPs-mediated MYC mRNA translation. MTAR1 enhanced binding between IGF2BPs and PABP1, thereby promoting MYC mRNA stability and increased MYC mRNA translation. In summary, MTAR1 is a novel MYC-related lncRNA that contributes to tumor progression by enhancing MYC translation through mediating PABP1/IGF2BPs liquid-liquid phase separation.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas c-myc / RNA Longo não Codificante / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas c-myc / RNA Longo não Codificante / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article